| IPO Date | July 9, 2025 to July 11, 2025 |
| Listing Date | July 16, 2025 |
| Face Value | ₹ 10 / Share |
| Price Band | ₹ 115 to ₹ 123 / Share |
| Lot Size | 1000 Shares |
| Total Issue Size | 22,41,000 shares (Aggregating up to ₹27.56 Cr) |
| Fresh Issue | |
| Offer for Sale | |
| Employee Discount | |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share holding pre issue | 62,71,360 shares |
| Share holding post issue | 85,12,360 shares |
| Market Maker portion | 1,13,000 shares |
Asston Pharmaceuticals Limited IPO opens on July 9, 2025, and closes on July 11, 2025.
| IPO Open Date | July 9, 2025 |
| IPO Close Date | July 11, 2025 |
| Basis of Allotment | July 14, 2025 |
| Initiation of Refunds | July 15, 2025 |
| Credit of Shares to Demat | July 15, 2025 |
| Listing Date | July 16, 2025 |
| Cut-off time for UPI mandate confirmation | July 11, 2025 |
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof. The following table depicts the minimum and maximum investment by individual investors (retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | Rs.246,000 |
| Retail (Max) | 2 | 2,000 | Rs.246,000 |
| S-HNI (Min) | 8 | 8,000 | Rs.984,000 |
| S-HNI (Max) | 8 | 8,000 | Rs.984,000 |
| B-HNI (Min) | 9 | 9,000 | Rs.1,107,000 |
| HNI (Min) |
| Share Holding Pre Issue | 68.76% |
| Share Holding Post Issue | 50.66% |
Asston Pharmaceuticals IPO offers total 22,41,000 shares. Out of which 10,60,000 (47.30%) allocated to QIB, 4,25,000 (18.96%) allocated to QIB, 3,22,000 (14.37%) allocated to NII, 7,46,000 (33.29%) allocated to RII and 6,35,000 (28.34%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | |
|
| Market Maker Shares Offered | 1,13,000 5.04% |
|
| Other Shares Offered | |
|
| QIB Shares Offered | 10,60,000 47.30% |
|
| NII (HNI) Shares Offered | 3,22,000 14.37% |
|
| bNII > ₹10L | |
|
| sNII < ₹10L | |
|
| Retail Shares Offered | 7,46,000 33.29% |
|
| Employee Shares Offered | |
|
| Total Shares Offered | 22,41,000 100% |
Asston Pharmaceuticals IPO raises ₹7.81 crore from anchor investors. Asston Pharmaceuticals IPO Anchor bid date is July 8, 2025.
| Bid Date | 2025-07-08 |
| Shares Offered | |
| Anchor Portion Size (In Cr.) | 7.81 |
| Anchor lock-in period end date for 50% shares (30 Days) | August 13, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | October 12, 2025 |
Asston Pharmaceuticals Limited was founded in 2019 and is a pharmaceutical company with a focus on international healthcare product exports.
The company sells a variety of goods, such as syrups, sachets, tablets, and capsules. Analgesics, antibiotics, antifungals, vitamins, and other therapeutic categories are all included in its product line.
The company mostly works on a principle-to-principle basis with different marketers, producing pharmaceutical items for direct sales as well as contract production or loan licensing.
High-quality manufacturing is ensured by the company's compliance with Quality Management System (QMS) standards, NQA (Nuclear Quality Assurance) accreditation, and FDA certification from both the Central and State FDA.
The market capitalization of Asston Pharmaceuticals IPO is ₹104.70 Cr.
| KPI | Values |
|---|---|
| ROE | 50.56% |
| ROCE | 51.25% |
| Debt/Equity | 0.68 |
| RoNW | 40.36% |
| P/BV | 12.07 |
| PAT Margin (%) | 17.27% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 6.90 | 9.32 |
| P/E (x) | 17.83 | 13.2 |
Asston Pharmaceuticals Limited 4th Floor, Office No. A-431 Balaji Bhavan, Plot No. 42A, Sector-11, CBD Belapur, Navi Mumbai, Thane Navi Mumbai, Maharashtra, 400614 Phone: +91 22 49731411 Email: [email protected] |
Maashitla Securities Private Limited Phone: +91-11-45121795-96 Email: [email protected] Website: https://maashitla.com/allotment-status/public-issues |
Lamfindia specializes in offering innovative financial solutions, including stock broker services, mutual fund investments, and IPO guidance.